Testosterone News and Research

Latest Testosterone News and Research

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.

5 Apr 2012

MAPK/ERK2 pathway plays a major role in mediating testosterone's effects

Testosterone, the primary male sex hormone, appears to have antidepressant properties, but the exact mechanisms underlying its effects have remained unclear. Nicole Carrier and Mohamed Kabbaj, scientists at Florida State University, are actively working to elucidate these mechanisms.

2 Apr 2012

WCMC receives SU2C-PCF Prostate Dream Team Translational Cancer Research Grant

An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.

2 Apr 2012

Anthropologists discover lower testosterone levels in Tsimane men

As part of an isolated indigenous group in central Bolivia, Tsimane men spend much of their time hunting, foraging, fishing, and clearing land by hand to grow crops. Their ability to maintain the physical activity required to survive each day might imply they have higher than average male testosterone levels.

29 Mar 2012

Intermittent androgen suppression therapy for prostate cancer

Androgen suppression - the inhibition of testosterone and other male hormones - is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form.

28 Mar 2012

Testosterone receptor may be a potential target for triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

26 Mar 2012

Male pattern baldness causes discovered

Most men start to go bald in middle age, with about 80% of men having some hair loss by the age of 70. Male pattern baldness is the most common type of hair loss for men, the National Institute of Health said. Symptoms include a thinning of hair at the hairline, eventually creating a U-shaped or horseshoe pattern of hair on both sides of the head. The male sex hormone testosterone plays a key role, as do genetic factors. They cause the hair follicles to shrink, eventually becoming so small that they are invisible, leading to the appearance of baldness. While treatment is not necessary, side effects including psychological stress and loss of self-esteem due to change in appearance can be experienced.

25 Mar 2012

Testosterone may play a role in treatment of triple negative breast cancer

23 Mar 2012

Columbia Labs fourth quarter total net revenues decrease to $6.4M

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2011.

8 Mar 2012

LA BioMed to honor Women & Infants physician as 'Legend'

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) recently announced that it will honor John E. Buster, MD, associate director of the Center for Reproduction and Infertility at Women & Infants Hospital of Rhode Island and Tufts Medical Center, as one of its three "Legends" this May.

28 Feb 2012

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

23 Feb 2012

Study aims to achieve early detection of heart disease

With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) - Dr. Matthew Budoff and Dr. Ronald Oudiz - continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

22 Feb 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Four new drugs can extend survival and prognosis of prostate cancer

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

17 Feb 2012

Transgender man falls pregnant and becomes a natural mother

A transgender man in his 30’s was able to carry a child after taking female hormones to reverse the effects of his female-to-male sex change treatment. The man from the West Midlands, UK is in a long-term relationship. It is not clear whether his partner is male or female. Medical ethics experts have called for a full inquiry into the issues surrounding transgender births, saying the interests of the child should not be risked to “fulfill the rights of an adult”.

13 Feb 2012

NTRR completes research and development of new erectile dysfunction treatment

With Neutra Corp.'s Pure Plus weight-loss supplement already in the midst of clinical trials, the company announced today that it has completed research and development of its next product in the Pure Plus line: an all-natural erectile dysfunction (ED) treatment.

13 Feb 2012

ED can lead to potential cardiovascular disease in men

More than 12 million men have type 2 diabetes and that number is growing at an alarming rate. A little talked about complication of this disease is erectile dysfunction (ED), which can lead to an even more serious condition.

7 Feb 2012

Scientists uncover genes that govern male and female behaviors

Hormones shape our bodies, make us fertile, excite our most basic urges, and as scientists have known for years, they govern the behaviors that separate men from women. But how? Now a team of scientists at the University of California, San Francisco (UCSF) has uncovered many genes influenced by the male and female sex hormones testosterone and estrogen that, in turn, govern several specific types of male and female behaviors in mice.

3 Feb 2012

Counterfeit Drugs - New technology to combat counterfeit

A brand new and patented technology has recently been launched that protects patients from buying and using counterfeit medicines. Pharmaceutical companies can now effectively and very economically protect their products and supply chain with this technology, thus avoiding damages and incalculable liabilities resulting from falsified products.

1 Feb 2012